A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer’s Disease

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works

Alzheimer's disease: the amyloid cascade hypothesis

Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · see citing works

The amyloid hypothesis of Alzheimer's disease at 25 years

Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · see citing works

Alzheimer’s disease

Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569 · see citing works

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works

Amyloid deposition as the central event in the aetiology of Alzheimer’s disease

Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · see citing works

2019 Alzheimer’s disease facts and figures.

Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461 · see citing works

Aβ Oligomers – a decade of discovery

Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938 · see citing works

The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease

Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918 · see citing works

Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline

Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · see citing works

Neuroinflammation in Alzheimer's disease: current evidence and future directions

Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726 · see citing works

Defeating Alzheimer's disease and other dementias: a priority for European science and society

Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676 · see citing works

An english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”

Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455 · see citing works

Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance

Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,227 · see citing works

Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease

Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188 · see citing works

Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers

Reitz, C., & Mayeux, R. P. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.024 · Cited by 1,180 · see citing works

Alzheimer’s disease is type 3 diabetes—Evidence reviewed

de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158 · see citing works

The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade

Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870 · see citing works

Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease

Kametani, F., & Hasegawa, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00025 · Cited by 836 · see citing works

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers

Bomfim, T. R., Forny‐Germano, L., Sathler, L. B., Brito‐Moreira, J., Houzel, J., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 830 · see citing works

Alzheimer's disease drug development pipeline: 2019

Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762 · see citing works

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698 · see citing works

Alzheimer's disease drug development pipeline: 2018

Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697 · see citing works

Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease

Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685 · see citing works

P-glycoprotein deficiency at the blood-brain barrier increases amyloid- deposition in an Alzheimer disease mouse model

Cirrito, J. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25247 · Cited by 660 · see citing works

Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers

De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657 · see citing works

Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease

Felice, F. G. D., & Ferreira, S. T. (2014) · Diabetes · doi:10.2337/db13-1954 · Cited by 647 · see citing works

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>

Green, R. C. (2009) · JAMA · doi:10.1001/jama.2009.1866 · Cited by 643 · see citing works

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Viola, K. L., & Klein, W. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1386-3 · Cited by 628 · see citing works

Tau and tauopathies

Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609 · see citing works

Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options

Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588 · see citing works

A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward

Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570 · see citing works

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567 · see citing works

Randomized trial of verubecestat for prodromal Alzheimer's disease

Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545 · see citing works

In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480 · see citing works

The risk of overweight/obesity in mid-life and late life for the development of dementia: a systematic review and meta-analysis of longitudinal studies

Pedditizi, E., Peters, R. K., & Beckett, N. S. (2016) · Age and Ageing · doi:10.1093/ageing/afv151 · Cited by 476 · see citing works

Relative Abundance of Alzheimer A Beta Amyloid Peptide Variants in Alzheimer Disease and normal Aging

Näslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., Roses, A. D., Tjernberg, L. O., Silberring, J., Gandy, S. E., Winblad, B., & Greengard, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8378 · Cited by 468 · see citing works

Therapeutic strategies for Alzheimer's disease in clinical trials

Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 454 · see citing works

Body mass index and risk of dementia: analysis of individual-level data from 1·3 million individuals

Kivimäki, M., Luukkonen, R., Batty, G. D., Ferrie, J. E., Pentti, J., Nyberg, S. T., Shipley, M. J., Alfredsson, L., Fransson, E. I., Goldberg, M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.016 · Cited by 440 · see citing works

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31275-2 · Cited by 427 · see citing works

Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II study

Singh‐Manoux, A., Dugravot, A., Shipley, M., Brunner, E. J., Elbaz, A., Sabia, S., & Kivimaki, M. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.06.2637 · Cited by 401 · see citing works

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Kennedy, M., Stamford, A., Chen, X., Cox, K., Cumming, J., Dockendorf, M., Egan, M. F., Ereshefsky, L., Hodgson, R., Hyde, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9704 · Cited by 391 · see citing works

The natural history of cognitive decline in Alzheimer's disease.

Wilson, R. S., Segawa, E., Boyle, P. A., Anagnos, S. E., Hizel, L. P., & Bennett, D. A. (2012) · Psychology and Aging · doi:10.1037/a0029857 · Cited by 386 · see citing works

Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin

Hsu, C.-C., Wahlqvist, M. L., Lee, M.-S., & Tsai, H.-N. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101524 · Cited by 372 · see citing works

Insulin Resistance and Neurodegeneration: Progress towards the Development of New Therapeutics for Alzheimer's Disease

de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331 · see citing works

Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies

Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331 · see citing works

Alzheimer’s disease and insulin resistance: translating basic science into clinical applications

Felice, F. G. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64595 · Cited by 328 · see citing works

Blood–brain barrier P-glycoprotein function in Alzheimer's disease

van Assema, D. M. E., Lubberink, M., Bauer, M., van der Flier, W. M., Schuit, R. C., Windhorst, A. D., Comans, E. F. I., Hoetjes, N. J., Tolboom, N., Langer, O., et al. (2012) · Brain · doi:10.1093/brain/awr298 · Cited by 318 · see citing works

Hippocampal Insulin Resistance Impairs Spatial Learning and Synaptic Plasticity

Grillo, C. A., Piroli, G. G., Lawrence, R. C., Wrighten, S. A., Green, A. J., Wilson, S. P., Sakai, R. R., Kelly, S. J., Wilson, M. A., Mott, D. D., et al. (2015) · Diabetes · doi:10.2337/db15-0596 · Cited by 308 · see citing works

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

Novák, P., Schmidt, R., Kontseková, E., Žilka, N., Kováčech, B., Škrabana, R., Kazmerova, Z., Katina, S., Fialová, Ľ., Prčina, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30331-3 · Cited by 306 · see citing works

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

Wilcock, G. K., Black, S. E., Hendrix, S. B., Zavitz, K. H., Swabb, E. A., & Laughlin, M. A. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70090-5 · Cited by 291 · see citing works

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

Logovinsky, V., Satlin, A., Lai, R. Y. K., Swanson, C. J., Kaplow, J. M., Osswald, G., Basun, H., & Lannfelt, L. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0181-2 · Cited by 289 · see citing works

Corrigenda

Pedditzi, E., Peters, R. K., & Beckett, N. S. (2016) · Age and Ageing · doi:10.1093/ageing/afw095 · Cited by 279 · see citing works

What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research

Šalković‐Petrišić, M., Knezović, A., Hoyer, S., & Riederer, P. F. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0877-9 · Cited by 272 · see citing works

Tau-aggregation inhibitor therapy for Alzheimer's disease

Wischik, C. M., Harrington, C. R., & Storey, J. M. D. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.008 · Cited by 263 · see citing works

ABBY

Cummings, J. L., Cohen, S., van Dyck, C. H., Brody, M., Curtis, C. T., Cho, W., Ward, M. E., Friesenhahn, M. J., Rabe, C., Brunstein, F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005550 · Cited by 254 · see citing works

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

Kontseková, E., Žilka, N., Kováčech, B., Novák, P., & Novák, M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt278 · Cited by 248 · see citing works

Insulin Reverses the High-Fat Diet–Induced Increase in Brain Aβ and Improves Memory in an Animal Model of Alzheimer Disease

Vandal, M., White, P. J., Tremblay, C., St‐Amour, I., Chevrier, G., Émond, V., Lefrançois, D., Virgili, J., Planel, E., Giguère, Y., et al. (2014) · Diabetes · doi:10.2337/db14-0375 · Cited by 232 · see citing works

Stop Alzheimer’s before it starts

McDade, E., & Bateman, R. J. (2017) · Nature · doi:10.1038/547153a · Cited by 228 · see citing works

Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type?

Hoyer, S., Oesterreich, K., & Wagner, O. (1988) · Journal of Neurology · doi:10.1007/bf00314304 · Cited by 224 · see citing works

Alzheimer disease and aducanumab: adjusting our approach

Selkoe, D. J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0205-1 · Cited by 208 · see citing works

Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease

Henley, D., Raghavan, N., Sperling, R., Aisen, P., Raman, R., & Romano, G. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1813435 · Cited by 197 · see citing works

Tau-Centric targets and drugs in clinical development for the treatment of alzheimer's disease

Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Zecca, C., Barulli, M. R., Bellomo, A., Pilotto, A., et al. (2016) · BioMed Research International · doi:10.1155/2016/3245935 · Cited by 195 · see citing works

Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood–Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease

Deo, A. K., Borson, S., Link, J. M., Domino, K., Eary, J. F., Ke, B., Richards, T. L., Mankoff, D. A., Minoshima, S., O’Sullivan, F., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.130161 · Cited by 193 · see citing works

Alzheimer’s Disease, Oligomers, and Inflammation

Forloni, G., & Balducci, C. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170819 · Cited by 192 · see citing works

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease

Ferrero, J., Williams, L., Stella, H., Leitermann, K., Mikulskis, A., O'Gorman, J., & Sevigny, J. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.002 · Cited by 189 · see citing works

New Approaches for the Treatment of Alzheimer’s Disease

Fish, P. V., Steadman, D., Bayle, E. D., & Whiting, P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.034 · Cited by 189 · see citing works

The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease

Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809316 · Cited by 177 · see citing works

Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice

Muhs, A., Hickman, D. T., Pihlgren, M., Chuard, N., Giriens, V., Meerschman, C., der Auwera, I. V., LEUVEN, F. V., Sugawara, M., Weingertner, M.-C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703137104 · Cited by 176 · see citing works

Causes and Consequences of Disturbances of Cerebral Glucose Metabolism in Sporadic Alzheimer Disease: Therapeutic Implications

Hoyer, S. (2004) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-8969-7_8 · Cited by 173 · see citing works

Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead

Kumar, D., Ganeshpurkar, A., Kumar, D., Modi, G. P., Gupta, S., & Singh, S. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.035 · Cited by 170 · see citing works

Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease

Landreth, G. E. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00296-2 · Cited by 169 · see citing works

Target Enzyme in Alzheimer’s Disease: Acetylcholinesterase Inhibitors

Saxena, M., & Dubey, R. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190128125912 · Cited by 168 · see citing works

The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review

Hoyer, S. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200082 · Cited by 161 · see citing works

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

Lannfelt, L., Möller, C., Basun, H., Osswald, G., Sehlin, D., Satlin, A., Logovinsky, V., & Gellerfors, P. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt246 · Cited by 152 · see citing works

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

Salloway, S., Honigberg, L. A., Cho, W., Ward, M. E., Friesenhahn, M. J., Brunstein, F., Quartino, A. L., Clayton, D., Mortensen, D. L., Bittner, T., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0424-5 · Cited by 151 · see citing works

UB‐311, a novel UBITh ^® amyloid β peptide vaccine for mild Alzheimer's disease

Wang, C. Y., Wang, P., Chiu, M., Finstad, C. L., Lin, F., Lynn, S., Tai, Y., De Fang, X., Zhao, K., Hung, C., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.03.005 · Cited by 150 · see citing works

FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease

Novak, P., Schmidt, R., Kontsekova, E., Kovacech, B., Smolek, T., Katina, S., Fialova, L., Prcina, M., Parrak, V., Dal-Bianco, P., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0436-1 · Cited by 147 · see citing works

Diabetes drugs in the fight against Alzheimer's disease

Boccardi, V., Murasecco, I., & Mecocci, P. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100936 · Cited by 142 · see citing works

Protective Role of Methylene Blue in Alzheimer's Disease via Mitochondria and Cytochrome c Oxidase

Atamna, H., & Kumar, R. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100414 · Cited by 137 · see citing works

Insulin-Resistant Brain State after Intracerebroventricular Streptozotocin Injection Exacerbates Alzheimer-like Changes in Tg2576 AβPP-Overexpressing Mice

Plaschke, K., Kopitz, J., Siegelin, M., Schliebs, R., Salkovic-Petrisic, M., Riederer, P., & Hoyer, S. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1270 · Cited by 118 · see citing works

Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice

Kastanenka, K. V., Bussière, T., Shakerdge, N. B., Qian, F., Weinreb, P. H., Rhodes, K., & Bacskai, B. J. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2080-16.2016 · Cited by 112 · see citing works

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: Randomized, double-blind, placebo-controlled study

Timmers, M., Streffer, J. R., Russu, A., Tominaga, Y., Shimizu, H., Shiraishi, A., Tatikola, K., Smekens, P., Börjesson-Hanson, A., Andreasen, N., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0415-6 · Cited by 112 · see citing works

Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

Lacosta, A.-M., Pascual-Lucas, M., Pesini, P., Casabona, D., Pérez-Grijalba, V., Marcos-Campos, I., Sarasa, L., Canudas, J., Badi, H., Monleón, I., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0340-8 · Cited by 111 · see citing works

A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease

Grundman, M., Morgan, R. E., Lickliter, J. D., Schneider, L. S., DeKosky, S. T., Izzo, N. J., Guttendorf, R. J., Higgin, M., Pribyl, J., Mozzoni, K., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.11.001 · Cited by 111 · see citing works

Systemic and CNS Inflammation Crosstalk: Implications for Alzheimer’s Disease

Paouri, E., & Georgopoulos, S. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321154618 · Cited by 108 · see citing works

Intranasal insulin in Alzheimer's disease: Food for thought

Chapman, C. D., Schiöth, H. B., Grillo, C. A., & Benedict, C. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.037 · Cited by 101 · see citing works

Cromolyn Reduces Levels of the Alzheimer’s Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis

Zhang, C., Griciuc, A., Hudry, E., Wan, Y., Quinti, L., Ward, J., Forte, A. M., Shen, X., Ran, C., Elmaleh, D. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19641-2 · Cited by 99 · see citing works

Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease

Wang, C. Y., Finstad, C. L., Walfield, A. M., Sia, C., Sokoll, K. K., Chang, T.-Y., Fang, X. D., Hung, C. H., Hutter-Paier, B., & Windisch, M. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.031 · Cited by 98 · see citing works

Why Alzheimer's is a disease of memory: The attack on synapses by Aß oligomers (ADDLs)

Viola, K. L., Velasco, P. T., & Klein, W. L. (2008) · The journal of nutrition health & aging · doi:10.1007/bf02982587 · Cited by 96 · see citing works

Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimer's Disease: A State-of-the-Art Review

Benedict, C., & Grillo, C. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00215 · Cited by 96 · see citing works

BACE inhibitors in clinical development for the treatment of Alzheimer’s disease

Panza, F., Lozupone, M., Solfrizzi, V., Sardone, R., Piccininni, C., Dibello, V., Stallone, R., Giannelli, G., Bellomo, A., Greco, A., et al. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1531706 · Cited by 92 · see citing works

Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress

Boada, M., López, O., Núñez, L., Szczepiorkowski, Z. M., Torres, M., Grifols, C., & Páez, A. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.01.001 · Cited by 91 · see citing works

The role of the metabolic lesion in Alzheimer's disease

Blass, J. P., Gibson, G. E., & Hoyer, S. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4312 · Cited by 90 · see citing works

Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's disease

Satlin, A., Wang, J., Logovinsky, V., Berry, S. M., Swanson, C. J., Dhadda, S., & Berry, D. A. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.01.001 · Cited by 88 · see citing works

Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.

Haeberlein, S. B., O'Gorman, J. T., Chiao, P.-C., Bussière, T., von Rosenstiel, P., Tian, Y., Zhu, Y., von Hehn, C., Gheuens, S., Skordos, L., et al. (2017) · PubMed · doi:10.14283/jpad.2017.39 · Cited by 88 · see citing works

Vascular Risk Factors and Alzheimer’s Disease: Blood-Brain Barrier Disruption, Metabolic Syndromes, and Molecular Links

He, J., Zhao, X., Xu, L., & Mao, C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190764 · Cited by 86 · see citing works

Sequence-independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases

Hickman, D. T., López-Deber, M. P., Ndao, D. M., Silva, A. B., Nand, D., Pihlgren, M., Giriens, V., Madani, R., St-Pierre, A., Karastaneva, H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.186338 · Cited by 83 · see citing works

Senile dementia and Alzheimer's disease. Brain blood flow and metabolism

Hoyer, S. (1986) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(86)90018-7 · Cited by 79 · see citing works

The 20-Year Voyage Aboard the Journal of Alzheimer's Disease: Docking at ‘Type 3 Diabetes’, Environmental/Exposure Factors, Pathogenic Mechanisms, and Potential Treatments

de la Monte, S. M., Tong, M., & Wands, J. R. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170829 · Cited by 75 · see citing works

Plasma Aβ42 correlates positively with increased body fat in healthy individuals

Balakrishnan, K., Verdile, G., Mehta, P. D., Beilby, J. P., Nolan, D. A., Galvao, D. A., Newton, R. U., Gandy, S., & Martins, R. N. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8305 · Cited by 74 · see citing works

New evolutions in the BACE1 inhibitor field from 2014 to 2018

Hsiao, C., Rombouts, F. J. R., & Gijsen, H. J. M. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.049 · Cited by 74 · see citing works

Insulin resistance and hippocampal dysfunction: Disentangling peripheral and brain causes from consequences

Grillo, C. A., Woodruff, J. L., Macht, V. A., & Reagan, L. P. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.04.012 · Cited by 74 · see citing works

Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors

Zuhl, A. M., Nolan, C. E., Brodney, M. A., Niessen, S., Atchison, K. P., Houle, C. D., Karanian, D. A., Ambroise, C., Brulet, J. W., Beck, E. M., et al. (2016) · Nature Communications · doi:10.1038/ncomms13042 · Cited by 73 · see citing works

Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer’s disease

Yan, R., Fan, Q., Zhou, J., & Vassar, R. J. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.025 · Cited by 71 · see citing works

BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides

Sakamoto, K., Matsuki, S., Matsuguma, K., Yoshihara, T., Uchida, N., Azuma, F., Russell, M., Hughes, G., Haeberlein, S. B., Alexander, R., et al. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.950 · Cited by 62 · see citing works

Novel targets in Alzheimer’s disease: A special focus on microglia

Balducci, C., & Forloni, G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.017 · Cited by 61 · see citing works

Are Antibodies Directed Against Amyloid-β (Aβ) Oligomers the Last Call For the Aβ Hypothesis of Alzheimer's Disease?

Panza, F., Lozupone, M., Dibello, V., Greco, A., Daniele, A., Seripa, D., Logroscino, G., & Imbimbo, B. P. (2018) · Immunotherapy · doi:10.2217/imt-2018-0119 · Cited by 60 · see citing works

Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients

Panza, F., Seripa, D., Solfrizzi, V., Imbimbo, B. P., Lozupone, M., Leo, A., Sardone, R., Gagliardi, G., Lofano, L., Creanza, B. C., et al. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1241232 · Cited by 59 · see citing works

TNF alpha inhibitors in Alzheimer's disease: A systematic review

Ekert, J. O., Gould, R. L., Reynolds, G., & Howard, R. J. (2018) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4871 · Cited by 50 · see citing works

Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer’s Disease

Sellés, M. C., Oliveira, M. M., & Ferreira, S. T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179925 · Cited by 50 · see citing works

[O2–14–05]: PRECLINICAL CHARACTERIZATION OF AN ANTIBODY [LY3303560] TARGETING AGGREGATED TAU

Alam, R., Driver, D. A., Wu, S., Lozano, E., Key, S., Hole, J. T., Hayashi, M. L., & Lu, J. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.07.227 · Cited by 45 · see citing works

Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation

O’Neill, B. T., Beck, E. M., Butler, C. R., Nolan, C. E., Gonzales, C., Zhang, L., Doran, S. D., Lapham, K., Buzon, L. M., Dutra, J. K., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00246 · Cited by 43 · see citing works

Tratamiento de la enfermedad de Alzheimer mediante terapia combinada de aféresis terapéutica y hemoféresis con albúmina e inmunoglobulina intravenosa: fundamentos y aproximación terapéutica al estudio AMBAR (Alzheimer Management By Albumin Replacement)

Boada, M., Ramos‐Fernández, E., Guivernau, B., Muñoz, F. J., Costa, M., Ortiz, A. M., Jorquera, J. I., Núñez, L., Torres, M., & Páez, A. (2014) · Neurología · doi:10.1016/j.nrl.2014.02.003 · Cited by 41 · see citing works

Alzheimer’s disease research: The future of BACE inhibitors

Burki, T. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31425-9 · Cited by 40 · see citing works

Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways

Ettcheto, M., Sánchez‐López, E., Pons, L., Busquets, O., Olloquequi, J., Beas‐Zárate, C., Pallàs, M., García, M. L., Auladell, C., Folch, J., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.06.003 · Cited by 39 · see citing works

Prevention of Alzheimer's disease by treating mild cognitive impairment with combinations chosen from eight available drugs

Fessel, J. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.09.019 · Cited by 37 · see citing works

THE ALZHEIMER’S PREVENTION INITIATIVE GENERATION PROGRAM: EVALUATING CNP520 EFFICACY IN THE PREVENTION OF ALZHEIMER’S DISEASE

López, C. L., Caputo, A., Liu, F., Riviere, M., Rouzade‐Dominguez, M., Thomas, R. G., Langbaum, J. B. S., Lenz, R., Reiman, E. M., Graf, A., et al. (2017) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2017.37 · Cited by 36 · see citing works

Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study

Boada, M., Ramos‐Fernández, E., Guivernau, B., Muñoz, F. J., Costa, M., Ortiz, A. M., Jorquera, J. I., Núñez, L., Torres, M., & Páez, A. (2016) · Neurología (English Edition) · doi:10.1016/j.nrleng.2014.02.009 · Cited by 34 · see citing works

Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Aβ deposition rate and plaque burden at treatment initiation

Brendel, M., Jaworska, A. M., Overhoff, F., Blume, T., Probst, F., Gildehaus, F., Bartenstein, P., Haass, C., Bohrmann, B., Herms, J. W., et al. (2018) · Theranostics · doi:10.7150/thno.27868 · Cited by 34 · see citing works

SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)

Pradier, L., Blanchard-Brégeon, V., Bohme, A., Debeir, T., Ménager, J., Benoit, P., Barnéoud, P., Taupin, V., Bertrand, P., Dugay, P., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0447-y · Cited by 34 · see citing works

BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants

Timmers, M., Barão, S., Broeck, B. V., Tesseur, I. C., Slemmon, J., Waepenaert, K. D., Bogert, J., Shaw, L. M. J., Engelborghs, S., Moechars, D., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160829 · Cited by 32 · see citing works

Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials

Soejitno, A., Tjan, A., & Purwata, T. E. (2015) · CNS Drugs · doi:10.1007/s40263-015-0257-8 · Cited by 31 · see citing works

Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers

Brazier, D., Perry, R., Keane, J., Barrett, K., & Elmaleh, D. R. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0549-5 · Cited by 31 · see citing works

Alois Alzheimer (1864–1915) and the Alzheimer syndrome

Sharma, V., Sourabh, A., & Harkirat, S. (2011) · Journal of Medical Biography · doi:10.1258/jmb.2010.010037 · Cited by 28 · see citing works

Neuroprotective Effects of the Amylin Analog, Pramlintide, on Alzheimer’s Disease Are Associated with Oxidative Stress Regulation Mechanisms

Patrick, S., Corrigan, R. R., Grizzanti, J., Mey, M., Blair, J., Pallàs, M., Camins, A., Lee, H., & Casadesús, G. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180421 · Cited by 27 · see citing works

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects

Qiu, R., Ahn, J. E., Alexander, R., Brodney, M. A., He, P., Leurent, C., Mancuso, J. Y., Margolin, R. A., Tankisheva, E., & Chen, D. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190228 · Cited by 27 · see citing works

Developing Disease-Modifying Treatments in Alzheimer's Disease - A Perspective from Roche and Genentech.

(2017) · PubMed · doi:10.14283/jpad.2017.40 · Cited by 23 · see citing works

Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain

Zhang, L., Chen, L. M., Dutra, J. K., Beck, E. M., Nag, S., Takano, A., Amini, N., Arakawa, R., Brodney, M. A., Buzon, L. M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01769 · Cited by 22 · see citing works

Highly Selective and Potent Human β‐Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X‐ray Structure and Structure–Activity Relationship Studies

Ghosh, A. K., Brindisi, M., Yen, Y., Lendy, E. K., Kovela, S., Cárdenas, E. L., Reddy, B. S., Rao, K. V., Downs, D., Huang, X., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201800725 · Cited by 22 · see citing works

Disease-modifying therapies for tauopathies: agents in the pipeline

Panza, F., Imbimbo, B. P., Lozupone, M., Greco, A., Seripa, D., Logroscino, G., Daniele, A., & Colosimo, C. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1606715 · Cited by 20 · see citing works

Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics

Ye, N., Monk, S. A., Daga, P., Bender, D. M., Rosen, L. B., Mullen, J., Minkwitz, M. C., & Kugler, A. R. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.422 · Cited by 17 · see citing works

Emerging amyloid and tau targeting treatments for Alzheimer’s disease

Khan, A., Corbett, A., & Ballard, C. G. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1326819 · Cited by 15 · see citing works

What We Learn from the CTAD 2018 (Clinical Trials Alzheimer's Disease)

Vellas, B. J., Aisen, P. S. S., Weiner, M. W., & Touchon, J. (2018) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2017.38 · Cited by 15 · see citing works

[P1–074]: PRECLINICAL DISCOVERY AND DEVELOPMENT OF MEDI1814, A MONOCLONAL ANTIBODY SELECTIVELY TARGETING BETA‐AMYLOID 42 (Aβ42)

Billinton, A., Newton, P., Lloyd, C., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.06.141 · Cited by 12 · see citing works

Cover Feature: Highly Selective and Potent Human β‐Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X‐ray Structure and Structure–Activity Relationship Studies (ChemMedChem 5/2019)

Ghosh, A. K., Brindisi, M., Yen, Y., Lendy, E. K., Kovela, S., Cárdenas, E. L., Reddy, B. S., Rao, K. V., Downs, D., Huang, X., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900100 · Cited by 9 · see citing works

Evaluation of an Allosteric BACE Inhibitor Peptide to Identify Mimetics that Can Interact with the Loop F Region of the Enzyme and Prevent APP Cleavage.

Campagna, J. J., Vadivel, K., Jagodzinska, B., Jun, M., Bilousova, T. V., Spilman, P., & John, V. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.04.002 · Cited by 5 · see citing works

P2‐123: The deposition of Aß40 in the brain is pathognomonic for Alzheimer‐type dementia in Down syndrome

Pesini, P., Lacosta, A. M., & Sarasa, M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.434 · Cited by 3 · see citing works

P2‐119: Relation of C‐reactive protein to cognitive impairment

Noble, J. M., Manly, J. J., Schupf, N., Tang, M. X., Mayeux, R. P., & Luchsinger, J. A. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.430 · Cited by 2 · see citing works

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease

Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works

Susquehanna Chorale Spring Concert "Roots and Wings"

Hawkins, D. (2017)

Genentech taps Affimed’s antibodies

Cross, R. (2018) · C&EN Global Enterprise · doi:10.1021/cen-09635-buscon15

KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK

Sari, D. (2023) · Jurnal Komplikasi Anestesi · doi:10.22146/jka.v5i1.7322

Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria

Dib, A., Puig, L. B., Salvadori, D., et al. (1988) · Arquivos Brasileiros de Cardiologia

Interleucinas na encefalopatia hipóxico-isquêmica

Ceccon, M. E. J. R. (2003) · Jornal de Pediatria · doi:10.1590/s0021-75572003000400002 · Cited by 14 · see citing works